Colfax Corporation Form 10-Q Summary
Reporting period: Three and six months ended July 2, 2021, compared with July 3, 2020. The filing identifies the registrant as Colfax Corporation, not Enovis Corp. Results cover continuing operations in Fabrication Technology and Medical Technology; asbestos-related and certain divested-business activity is reported as discontinued operations.
Business Context
Colfax operated through ESAB-branded Fabrication Technology and DJO-branded Medical Technology. Management announced a planned separation of these businesses into two independent publicly traded companies, targeted for the first quarter of 2022, subject to financing, regulatory approvals, tax treatment, market conditions, and board approval.
Key Financial Metrics
| Metric | Q2 2021 | Q2 2020 | Six Months 2021 | Six Months 2020 |
|---|---|---|---|---|
| Net sales | $985.9 million | $620.4 million | $1,865.1 million | $1,436.7 million |
| Gross profit | $419.0 million | $241.1 million | $790.1 million | $589.3 million |
| Gross margin | 42.5% | 38.9% | 42.4% | 41.0% |
| Operating income | $75.9 million | $(4.9) million | $137.2 million | $41.9 million |
| Continuing-operations net income | $31.3 million | $(3.1) million | $59.0 million | $5.7 million |
| Net income attributable to Colfax | $28.6 million | $(8.5) million | $47.7 million | $(4.0) million |
| Diluted EPS, consolidated | $0.18 | $(0.06) | $0.32 | $(0.03) |
| Adjusted EBITA | $130.3 million | $45.1 million | $237.4 million | $140.6 million |
| Adjusted EBITA margin | 13.2% | 7.3% | 12.7% | 9.8% |
Cash Flow, Liquidity and Debt
- Six-month operating cash flow was $162.8 million, versus $93.2 million in the prior-year period.
- Capital expenditures were $44.6 million; acquisitions and investments used $230.7 million.
- Cash and cash equivalents were $62.3 million at July 2, 2021, down from $97.1 million at December 31, 2020. The prior-year-end balance included $4.0 million of restricted cash.
- Total debt was approximately $1.60 billion, down from $2.23 billion at December 31, 2020. Long-term debt was $1.58 billion.
- The company used proceeds from a March equity offering to redeem all $600 million of its 2024 notes and $100 million of its 2026 notes. The redemptions generated $29.9 million of debt extinguishment charges, including a $24.4 million call premium.
- The $975 million revolving credit facility had $890 million available at July 2, 2021. The weighted-average borrowing rate under the credit facility was 1.84%, and the company was in compliance with its covenants.
- Management stated that available liquidity was adequate to fund operations for the next twelve months.
Material Changes Versus the Prior Comparable Period
- Sales increased 58.9% in the quarter and 29.8% year to date, primarily reflecting recovery from COVID-19-related weakness in 2020. Existing-business sales contributed $317.8 million of quarterly growth and $352.1 million of six-month growth.
- Fabrication Technology sales increased to $629.8 million from $414.4 million in the quarter; segment operating income increased to $94.4 million from $43.6 million.
- Medical Technology sales increased to $356.1 million from $206.0 million; segment operating income improved to $18.2 million from a $20.8 million loss.
- Gross margins improved overall, although Fabrication Technology experienced inflationary pressure and higher supply-chain costs. Medical Technology benefited from higher volumes and acquisitions.
- Selling, general and administrative expense increased because of higher commissions, acquired-business expenses, and the cessation of temporary COVID-related cost reductions implemented in 2020.
- The company recognized an $11.2 million pension settlement gain, partially offset by the $29.9 million debt extinguishment charge.
- Six-month acquisitions and investments totaled approximately $230.7 million, including the Trilliant Surgical and MedShape acquisitions. A further acquisition of Mathys AG Bettlach, for approximately $285 million expected to be funded with common stock, was expected to close July 28, 2021, subject to closing conditions.
Guidance, Outlook, Risks and Unusual Items
- No specific quantitative full-year revenue or earnings guidance is provided in the filing text.
- Management reported normalization of sales volumes in most markets as vaccination access increased and restrictions eased, but stated that the future impact of COVID-19 variants and related government actions remains difficult to estimate.
- The planned separation may be delayed, not completed, or fail to deliver anticipated benefits. It requires financing, regulatory approvals, a favorable tax opinion or IRS ruling, and final board approval. Failure to qualify for generally tax-free treatment could create significant tax liabilities.
- Key operating risks include inflation and commodity costs, supply-chain disruptions, raw-material availability, foreign exchange exposure, interest-rate risk, product liability, acquisitions and integration, cybersecurity, regulatory compliance, and impairment of goodwill or intangible assets.
- Asbestos-related claims remain material. Unresolved claims increased to 15,380 at July 2, 2021 from 14,809 at December 31, 2020. Recorded asbestos liabilities totaled approximately $291.2 million, supported by insurance assets and receivables totaling approximately $253.8 million. Actual liabilities and recoveries could differ materially.
- Discontinued operations produced losses of $1.6 million in the quarter and $9.1 million year to date, primarily from asbestos-related activity and divested-business matters.
- A 1% increase in variable interest rates would have increased interest expense by approximately $2.3 million for the quarter and $4.3 million for the six-month period. A 10% depreciation in major currencies against the U.S. dollar would have reduced equity by approximately $169 million, net of hedging effects.
Investor Verification Checklist
- Confirm the issuer identity: the supplied filing is for Colfax Corporation, while the request metadata names Enovis Corp.
- Verify the planned separation timeline, financing structure, tax-free status, regulatory approvals, and final transaction terms.
- Assess whether improved results reflect sustainable operating recovery or favorable comparison against the COVID-affected 2020 period.
- Monitor inflation, supply-chain costs, pricing actions, and their impact on Fabrication Technology margins.
- Review the Mathys acquisition closing, share issuance, integration costs, and resulting dilution.
- Evaluate liquidity after acquisitions, debt redemptions, and the required January 2022 TEU settlement.
- Track asbestos claims, insurance recoveries, insurer solvency, and potential changes in recorded liabilities.
- Reconcile management’s non-GAAP Adjusted EBITA with GAAP results, particularly the effects of acquisition amortization, strategic transaction costs, debt extinguishment, and the pension settlement gain.